Tirzepatide Pilot Study Explores Muscle and Bone Health in Older Adults with Obesity

Obesity is a significant health challenge, particularly in older adults, often leading to comorbidities like type 2 diabetes and cardiovascular disease. While GLP-1 receptor agonists like Tirzepatide are highly effective for weight loss, there's a critical concern about preserving fat-free mass (FFM), which includes muscle and bone, during rapid weight reduction. Losing FFM can exacerbate sarcopenia (age-related muscle loss) and osteopenia (reduced bone density), increasing frailty and fracture risk. This pilot study directly addresses the knowledge gap regarding Tirzepatide's specific effects on FFM, bone health, and physical function in older adults with obesity.

As an active pilot study (NCT06861439), specific results are not yet available; however, the study aims to uncover crucial data regarding Tirzepatide's impact on key physiological parameters in older adults with obesity. Researchers will meticulously measure changes in fat-free mass (FFM), bone mineral density (BMD), and various physical function metrics over the 9-month intervention. The primary objective is to determine if Tirzepatide can effectively promote weight loss while simultaneously preserving or even enhancing muscle mass and bone strength, thereby mitigating the risks of sarcopenia and osteopenia. > The central hypothesis is that Tirzepatide will demonstrate a favorable effect on fat-free mass and bone health, potentially leading to a greater preservation of muscle and bone compared to typical weight loss interventions, alongside significant reductions in overall body weight. Secondary outcomes will include quantifying improvements in physical performance tests, assessing the safety and tolerability profile of Tirzepatide at doses up to 5 mg weekly in this population, and analyzing the impact on daily step counts and dietary intake patterns.